In this issue of Blood , Lamy et al present the results of the LYSA/GOELAMS trial 02-03, where patients with limited-stage diffuse large B-cell lymphoma (DLBCL) received either 4 or 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) based on risk stratification, and those achieving complete response (CR) by positron emission tomography (PET) after 4 cycles either received 40 Gy of radiation or were observed. The outcomes were excellent regardless of radiation administration, which was not surprising because the study enrolled a favorable-risk cohort of patients. The role of radiation therapy (RT) is hard to discern in this setting. 1

中文翻译：

---

限期 DLBCL：患者选择

在本期血液中，Lamy 等人介绍了 LYSA/GOELAMS 试验 02-03 的结果，其中局限期弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者接受了 4 或 6 个周期的利妥昔单抗加环磷酰胺、多柔比星、基于风险分层的长春新碱和强的松 (R-CHOP)，以及在 4 个周期后通过正电子发射断层扫描 (PET) 获得完全缓解 (CR) 的患者接受 40 Gy 辐射或观察。无论放射治疗如何，结果都非常好，这并不奇怪，因为该研究招募了一个有利风险的患者队列。在这种情况下很难辨别放射治疗 (RT) 的作用。1